View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
FRIDAY, June 22 (HealthDay News) -- For patients with peripheral artery disease (PAD), treatment with the platelet inhibitor vorapaxar significantly reduces the risk of hospitalization for acute limb ischemia and arterial revascularization, according to a study presented during the American Heart Association's Emerging Science Series Webinar, held on June 20.
Marc P. Bonaca, M.D., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues conducted a randomized placebo-controlled trial of 2.5 mg daily vorapaxar in addition to standard care, involving 3,787 patients with PAD. Participants with a history of claudication symptoms and either an ankle brachial index of <0.85 or prior peripheral revascularization for limb ischemia were deemed eligible.
The researchers observed no significant difference in the primary end point (composite of cardiovascular death, myocardial infarction, or stroke) in patients receiving vorapaxar or placebo. For patients randomized to vorapaxar there were significantly lower rates of hospitalization for acute limb ischemia (2.3 versus 3.9 percent; P = 0.006) and peripheral arterial revascularization (18.4 versus 22.2 percent; P = 0.017). Vorapaxar was associated with a significantly increased risk of bleeding, including intracerebral hemorrhage.
"This is the first outpatient therapy that has been shown to reduce the risk of blood clots and the need for artery opening revascularization procedures in the legs in patients with PAD," Escolar said in a statement. "For clinicians and researchers, these data show the potential for therapies that can reduce leg problems in patients with PAD rather than just overall cardiovascular risk."
Several authors disclosed financial ties to pharmaceutical companies, including Merck, which funded the study and developed vorapaxar.
Find in-depth content on major issues provided by leading companies in partnership with NursingCenter.com
BD Safety Beyond Needlestick Prevention Learning Center
Sponsored by BD Medical
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top